🔎 Trials Near Me

Akèy › Twoub depresif majè › Florid › Orlando

Etid klinik pou Twoub depresif majè nan Orlando, FL

19 etid pou Twoub depresif majè ap chèche patisipan nan sit nan ak bò kote Orlando (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.

Tèks ofisyèl etid la (Anglè)

Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →

Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms

Ap rekriteFaz 3
  • Nova Psychiatry INC, Orlando
Laj 18 a 74 · Tout sèks · Mizajou Sep 25, 2026 · NCT06559306

A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)

Ap rekriteFaz 2
  • Clinical Neuroscience Solutions Inc. - Orlando, Orlando
  • K2 Medical Research - Maitland, Maitland · 6 mi lwen
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07621237

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

Ap rekriteFaz 3
  • Accel Research Sites - Maitland, Maitland · 6 mi lwen
Laj 18 a 85 · Tout sèks · Mizajou Sep 25, 2026 · NCT06793397

A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)

Ap rekriteFaz 2
  • Seaport Investigator Site, Orlando
Laj 18 a 65 · Tout sèks · Mizajou Sep 14, 2026 · NCT07065240

ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response

Ap rekriteFaz 2
  • Clinical Neuroscience Solutions, Inc., Orlando
Laj 18 a 65 · Tout sèks · Mizajou Sep 14, 2026 · NCT07284667

A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression

Ap rekriteFaz 2
  • Draig Clinical Site, Orlando
  • Draig Clinical Site, Orlando
Laj 18 a 75 · Tout sèks · Mizajou Sep 2, 2026 · NCT07610473

A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression

Ap rekriteFaz 2
  • Draig Clinical Site, Orlando
Laj 18 a 75 · Tout sèks · Mizajou Aug 26, 2026 · NCT07300969

A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)

Ap rekriteFaz 3
  • Clinical Neuroscience Solutions, LLC (Orlando), Orlando
  • Charter Research, Orlando
  • K2 Medical Research (Maitland), Maitland · 6 mi lwen
Laj 18 a 74 · Tout sèks · Mizajou Aug 10, 2026 · NCT07592689

NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

Ap rekriteFaz 3
  • Neurocrine Clinical Site, Maitland · 6 mi lwen
Laj 18 ak plis · Tout sèks · Mizajou Aug 10, 2026 · NCT06963021

A Study of Brenipatide in Adult Participants With Major Depressive Disorder

Ap rekriteFaz 3
  • Charter Research - Orlando, Orlando
  • K2 Medical Research - Maitland, Maitland · 6 mi lwen
Laj 18 a 75 · Tout sèks · Mizajou Aug 6, 2026 · NCT07412756

A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder

Ap rekriteFaz 3
  • Clinical Neuroscience Solutions, Inc., Orlando
Laj 18 a 74 · Tout sèks · Mizajou Aug 3, 2026 · NCT06775379

Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder

Ap rekriteFaz 2
  • Clinical Neuroscience Solutions, Inc., Orlando
Laj 18 a 64 · Tout sèks · Mizajou Aug 3, 2026 · NCT06547489

A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

Ap rekriteFaz 3
  • Neurocrine Clinical Site, Orlando
Laj 18 ak plis · Tout sèks · Mizajou Jul 24, 2026 · NCT07196501

Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

Ap rekriteFaz 3
  • Neurocrine Clinical Site, Maitland · 6 mi lwen
  • Neurocrine Clinical Site, Maitland · 6 mi lwen
Laj 18 ak plis · Tout sèks · Mizajou Jul 24, 2026 · NCT06966401

A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder

Ap rekriteFaz 2
  • Clinical Neuroscience Solutions - Orlando - East South Street /ID# 277558, Orlando
Laj 18 a 65 · Tout sèks · Mizajou Jun 15, 2026 · NCT07276997

Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

Ap rekriteFaz 3
  • Neurocrine Clinical Site, Maitland · 6 mi lwen
Laj 18 ak plis · Tout sèks · Mizajou Oct 29, 2025 · NCT06786624

Targeting Network Dysfunction in Apathy of Late-life Depression Using Digital Therapeutics

Ap rekrite
  • AdventHealth Neuroscience Institute, Orlando
Laj 60 ak plis · Tout sèks · Mizajou Oct 22, 2025 · NCT05877885

Study of ALTO-300 in MDD

Ap rekriteFaz 2
  • Site 159, Clermont · 24 mi lwen
Laj 18 a 70 · Tout sèks · Mizajou Jul 24, 2025 · NCT05922878

A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms

Ap rekriteFaz 4
  • Clinical Research Site, Orlando
  • Clinical Research Site, Orlando
  • Clinical Research Site, Orlando
Laj 18 a 65 · Tout sèks · Mizajou Jan 23, 2025 · NCT06223880

Etid Twoub depresif majè nan lòt vil

Lòt etid nan Orlando

Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.